These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 38606822)

  • 1. QL1604 plus paclitaxel-cisplatin/carboplatin in patients with recurrent or metastatic cervical cancer: an open-label, single-arm, phase II trial.
    Fang C; Zhou Y; Feng Y; He L; Yu J; Li Y; Feng M; Pan M; Zhao L; Tang D; Li X; Tan B; An R; Zheng X; Si M; Zhang B; Li L; Kang X; Zhou Q; Liu J
    J Gynecol Oncol; 2024 Nov; 35(6):e77. PubMed ID: 38606822
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized phase III trial of platinum chemotherapy plus paclitaxel with bevacizumab and atezolizumab versus platinum chemotherapy plus paclitaxel and bevacizumab in metastatic (stage IVB), persistent, or recurrent carcinoma of the cervix: the BEATcc study (ENGOT-Cx10/GEICO 68-C/JGOG1084/GOG-3030).
    Grau JF; Farinas-Madrid L; Oaknin A
    Int J Gynecol Cancer; 2020 Jan; 30(1):139-143. PubMed ID: 31645423
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Camrelizumab Plus Apatinib in Patients With Advanced Cervical Cancer (CLAP): A Multicenter, Open-Label, Single-Arm, Phase II Trial.
    Lan C; Shen J; Wang Y; Li J; Liu Z; He M; Cao X; Ling J; Huang J; Zheng M; Zou G; Yan H; Liu Q; Yang F; Wei W; Deng Y; Xiong Y; Huang X
    J Clin Oncol; 2020 Dec; 38(34):4095-4106. PubMed ID: 33052760
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of ramucirumab plus carboplatin and paclitaxel in untreated metastatic thymic carcinoma: RELEVENT phase II trial (NCT03921671).
    Proto C; Ganzinelli M; Manglaviti S; Imbimbo M; Galli G; Marabese M; Zollo F; Alvisi MF; Perrino M; Cordua N; Borea F; de Vincenzo F; Chella A; Cappelli S; Pardini E; Ballatore Z; Lucarelli A; Ambrosini E; Giuliano M; Pietroluongo E; Mulargiu C; Fabbri A; Prelaj A; Occhipinti M; Brambilla M; Mazzeo L; Beninato T; Vigorito R; Ruggirello M; Greco FG; Calareso G; Miliziano D; Rulli E; De Simone I; Torri V; de Braud FGM; Pasello G; De Placido P; Berardi R; Petrini I; Zucali P; Garassino MC; Lo Russo G
    Ann Oncol; 2024 Sep; 35(9):817-826. PubMed ID: 38857846
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Primary results from CECILIA, a global single-arm phase II study evaluating bevacizumab, carboplatin and paclitaxel for advanced cervical cancer.
    Redondo A; Colombo N; McCormack M; Dreosti L; Nogueira-Rodrigues A; Scambia G; Lorusso D; Joly F; Schenker M; Ruff P; Estevez-Diz M; Irahara N; Donica M; Gonzalez-Martín A
    Gynecol Oncol; 2020 Oct; 159(1):142-149. PubMed ID: 32763109
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A multi-institutional phase II trial of paclitaxel and carboplatin in the treatment of advanced or recurrent cervical cancer.
    Kitagawa R; Katsumata N; Ando M; Shimizu C; Fujiwara Y; Yoshikawa H; Satoh T; Nakanishi T; Ushijima K; Kamura T
    Gynecol Oncol; 2012 May; 125(2):307-11. PubMed ID: 22333993
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Paclitaxel Plus Carboplatin Versus Paclitaxel Plus Cisplatin in Metastatic or Recurrent Cervical Cancer: The Open-Label Randomized Phase III Trial JCOG0505.
    Kitagawa R; Katsumata N; Shibata T; Kamura T; Kasamatsu T; Nakanishi T; Nishimura S; Ushijima K; Takano M; Satoh T; Yoshikawa H
    J Clin Oncol; 2015 Jul; 33(19):2129-35. PubMed ID: 25732161
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized phase II/III trial of conventional paclitaxel and carboplatin with or without bevacizumab versus dose-dense paclitaxel and carboplatin with or without bevacizumab, in stage IVB, recurrent, or persistent cervical carcinoma (JCOG1311): Primary analysis.
    Ishikawa M; Shibata T; Iwata T; Nishio S; Takada T; Suzuki S; Horie K; Kudaka W; Kagabu M; Tanikawa M; Kitagawa R; Takekuma M; Kobayashi H; Yaegashi N;
    Gynecol Oncol; 2021 Aug; 162(2):292-298. PubMed ID: 34016453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pembrolizumab Plus Carboplatin and Paclitaxel as First-Line Therapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-B10): A Single-Arm Phase IV Trial.
    Dzienis M; Cundom J; Fuentes CS; Spreafico A; Nordlinger M; Pastor AV; Alesi E; Neki A; Fung AS; Figueiredo Lima IP; Oppelt P; da Cunha Junior GF; Burtness B; Franke FA; Tseng JE; Joshi A; McCarthy J; Swaby R; Sidi Y; Gumuscu B; Naicker N; de Castro G
    J Clin Oncol; 2024 Sep; 42(25):2989-2999. PubMed ID: 39038265
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase Ib study of duligotuzumab (MEHD7945A) plus cisplatin/5-fluorouracil or carboplatin/paclitaxel for first-line treatment of recurrent/metastatic squamous cell carcinoma of the head and neck.
    Jimeno A; Machiels JP; Wirth L; Specenier P; Seiwert TY; Mardjuadi F; Wang X; Kapp AV; Royer-Joo S; Penuel E; McCall B; Pirzkall A; Clement PM
    Cancer; 2016 Dec; 122(24):3803-3811. PubMed ID: 27525588
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of nanoparticle albumin-bound paclitaxel plus carboplatin as neoadjuvant chemotherapy for stages III-IV, unresectable ovarian cancer: a single-arm, open-label, phase Ib/II study.
    Yin L; Jiang W; Liu S; Fu Y; Zhou L; Pei X; Ye S; Shen W; Yang H; Shan B
    BMC Med; 2024 Oct; 22(1):496. PubMed ID: 39468597
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nab-paclitaxel plus platinum versus paclitaxel plus platinum as first-line therapy in patients with metastatic or recurrent cervical cancer.
    Liu Y; Fang SS; Zhao RS; Liu B; Jin YQ; Li Q
    J Cancer Res Clin Oncol; 2024 Jun; 150(6):321. PubMed ID: 38914827
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Atezolizumab Plus nab-Paclitaxel in the Treatment of Metastatic Triple-Negative Breast Cancer With 2-Year Survival Follow-up: A Phase 1b Clinical Trial.
    Adams S; Diamond JR; Hamilton E; Pohlmann PR; Tolaney SM; Chang CW; Zhang W; Iizuka K; Foster PG; Molinero L; Funke R; Powderly J
    JAMA Oncol; 2019 Mar; 5(3):334-342. PubMed ID: 30347025
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial.
    West H; McCleod M; Hussein M; Morabito A; Rittmeyer A; Conter HJ; Kopp HG; Daniel D; McCune S; Mekhail T; Zer A; Reinmuth N; Sadiq A; Sandler A; Lin W; Ochi Lohmann T; Archer V; Wang L; Kowanetz M; Cappuzzo F
    Lancet Oncol; 2019 Jul; 20(7):924-937. PubMed ID: 31122901
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety results from OCTAVIA, a single-arm phase II study evaluating front-line bevacizumab, carboplatin and weekly paclitaxel for ovarian cancer.
    Gonzalez-Martin A; Gladieff L; Tholander B; Stroyakovsky D; Gore M; Scambia G; Kovalenko N; Oaknin A; Ronco JP; Freudensprung U; Pignata S;
    Eur J Cancer; 2013 Dec; 49(18):3831-8. PubMed ID: 24007819
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A single-arm study evaluating bevacizumab, cisplatin, and paclitaxel followed by single-agent bevacizumab in Japanese patients with advanced cervical cancer.
    Sugiyama T; Mizuno M; Aoki Y; Sakurai M; Nishikawa T; Ueda E; Tajima K; Takeshima N
    Jpn J Clin Oncol; 2017 Jan; 47(1):39-46. PubMed ID: 27803033
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cediranib combined with carboplatin and paclitaxel in patients with metastatic or recurrent cervical cancer (CIRCCa): a randomised, double-blind, placebo-controlled phase 2 trial.
    Symonds RP; Gourley C; Davidson S; Carty K; McCartney E; Rai D; Banerjee S; Jackson D; Lord R; McCormack M; Hudson E; Reed N; Flubacher M; Jankowska P; Powell M; Dive C; West CML; Paul J
    Lancet Oncol; 2015 Nov; 16(15):1515-1524. PubMed ID: 26474517
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A retrospective analysis of cisplatin/carboplatin plus paclitaxel in advanced or recurrent cervical cancer.
    Song D; Kong W; Zhang T; Han C; Liu T; Jiao S; Chen J
    J Obstet Gynaecol; 2019 Apr; 39(3):389-394. PubMed ID: 30663464
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology-Gynecologic Oncology Group protocol 240).
    Penson RT; Huang HQ; Wenzel LB; Monk BJ; Stockman S; Long HJ; Ramondetta LM; Landrum LM; Oaknin A; Reid TJ; Leitao MM; Method M; Michael H; Tewari KS
    Lancet Oncol; 2015 Mar; 16(3):301-11. PubMed ID: 25638326
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial.
    Pfisterer J; Shannon CM; Baumann K; Rau J; Harter P; Joly F; Sehouli J; Canzler U; Schmalfeldt B; Dean AP; Hein A; Zeimet AG; Hanker LC; Petit T; Marmé F; El-Balat A; Glasspool R; de Gregorio N; Mahner S; Meniawy TM; Park-Simon TW; Mouret-Reynier MA; Costan C; Meier W; Reinthaller A; Goh JC; L'Haridon T; Baron Hay S; Kommoss S; du Bois A; Kurtz JE;
    Lancet Oncol; 2020 May; 21(5):699-709. PubMed ID: 32305099
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.